Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686933 · ClinicalTrials.gov registry record · Phase 2
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT00686933 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 117 participants.
The verdict
NCT00686933, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Interventions
- DRUG ABT-089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686933
The ClinicalTrials.gov registry entry for NCT00686933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-089 is the first listed.
NCT00686933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686933 about?
NCT00686933 is a clinical study titled "Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
What is the current status of trial NCT00686933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2008-05. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00686933?
The interventions under investigation include: ABT-089 (DRUG).
Who is sponsoring clinical trial NCT00686933?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.